NASDAQ:CDNA - CareDx Stock Price, Forecast & News

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx Inc (NASDAQ:CDNA) posted its quarterly earnings data on Thursday, February, 27th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.20. The company earned $35.82 million during the quarter, compared to analysts' expectations of $35.90 million. CareDx had a negative return on equity of 21.92% and a negative net margin of 18.25%. CareDx's revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.01 earnings per share. View CareDx's Earnings History.

CareDx is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for CareDx.

CareDx issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $165-168 million, compared to the consensus revenue estimate of $170.42 million.

5 equities research analysts have issued 1-year price objectives for CareDx's stock. Their forecasts range from $43.00 to $63.00. On average, they expect CareDx's stock price to reach $53.00 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View Analyst Price Targets for CareDx.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

Media coverage about CDNA stock has been trending very negative on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for CareDx.

CareDx saw a increase in short interest in February. As of February 14th, there was short interest totalling 5,500,000 shares, an increase of 14.1% from the January 30th total of 4,820,000 shares. Based on an average daily trading volume, of 714,300 shares, the short-interest ratio is currently 7.7 days. Approximately 13.4% of the shares of the company are short sold. View CareDx's Current Options Chain.

Some companies that are related to CareDx include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include EXACT Sciences (EXAS), Roku (ROKU), Alibaba Group (BABA), Aduro BioTech (ADRO), Tandem Diabetes Care (TNDM), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Square (SQ) and AbbVie (ABBV).

CareDx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (12.22%), State Street Corp (6.04%), Credit Suisse AG (3.24%), Casdin Capital LLC (2.83%), Gagnon Securities LLC (2.33%) and Lord Abbett & CO. LLC (1.89%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.

CDNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, State Street Corp, Goldman Sachs Group Inc., Rafferty Asset Management LLC, UBS Group AG, Citigroup Inc., AQR Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King and William A Hagstrom. View Insider Buying and Selling for CareDx.

CDNA stock was bought by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Fred Alger Management LLC, Sumitomo Mitsui Trust Holdings Inc., Schonfeld Strategic Advisors LLC, Nikko Asset Management Americas Inc., ARK Investment Management LLC, Bamco Inc. NY and Royce & Associates LP. View Insider Buying and Selling for CareDx.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDNA stock can currently be purchased for approximately $21.61.

CareDx has a market capitalization of $917.13 million and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.

The official website for CareDx is http://www.caredxinc.com/.

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]